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initiation/intensiﬁcation in patients uncontrolled on their current
therapy. RESULTS: The median time to intensiﬁcation of insulin
regimen for T1 patients uncontrolled on premix regimens, was
4.0 years (95% CI 3.2 to 5.4). The median time to initiation of
insulin for T2 patients, prescribed two or more oral agents, with
evidence of poor glycaemic control was 7.0 years (95% CI 6.5
to 7.7). Finally, the median time to intensiﬁcation of the insulin
regimen was 4.2 years (95% CI 3.5 to 6.1) for T2 patients
uncontrolled on a basal regimen and >8 years for those uncon-
trolled on a premix regimen. CONCLUSION: In spite of poor
glycaemic control, insulin-naïve and insulin-treated patients fail
to initiate/intensify insulin therapy for many years. Earlier initi-
ation/intensiﬁcation of insulin therapy is likely to lead to better
control and a reduction in the complications associated with dia-
betes. Barriers to insulin use must be overcome if patients are to
achieve appropriate control.
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OBJECTIVES: As part of the submission to NICE, we evaluated
the cost-effectiveness of inhaled insulin (INH) in patients with
type 1 diabetes uncontrolled on a premix regimen (T1), and
patients with type 2 diabetes uncontrolled on oral anti-diabetic
drugs (T2). METHODS: Using the perspective of the National
Health Service (NHS), a validated Markov model (EAGLE) was
used to estimate the incremental costs and QALYs gained of: 1)
a basal bolus regimen involving INH versus an injected basal
bolus regimen in T1; and 2) a bolus of INH versus i) an injected
basal regimen and ii) an injected premix regimen in T2. The
model simulates the progression of diabetes in 1000 patients over
a time frame of 20 years. A large UK dataset was used to docu-
ment the patients’ clinical characteristics. NHS reference costs
were used as a source for medical costs. Utility/disutility data
were collected in published studies and clinical trial data were
used to document the efﬁcacy of therapies. An annual 3.5% dis-
count rate was used for both costs and outcomes. Probabilistic
sensitivity analysis was performed. RESULTS: In T1 the total
incremental costs (IC) were ≤202,746 and the total QALYs
gained (IE) were 24, leading to a mean incremental cost-effec-
tiveness ratio (ICER) of ≤8510/QALY. In T2, the mean lCER
versus basal was ≤24,285/QALY with IC of ≤497,749 and IE of
21. The mean ICER versus premix was ≤24,555/QALY with IC
of ≤503,185 and IE of 21. The probabilistic sensitivity analysis
showed that for a willingness to pay of ≤30,000 per QALY
gained, INH was cost-effective in 100% of the T1 simulations
and in 92 to 95% of T2 simulations. CONCLUSION: INH is a
cost-effective therapy for T1 and T2 patients uncontrolled on
their current therapy in the UK setting.
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OBJECTIVES: The objective of the study was to translate and
linguistically validate the Satisfaction with Oral Anti-Diabetic
Agents (SOADA) questionnaire for use in 11 countries. The
questionnaire was developed in the United States in 2005 in
order to assess satisfaction with oral anti-diabetic medication in
patients with type 2 diabetes. METHODS: The accepted stan-
dard methodology was used: 2 forward translations, reconcilia-
tion, 2 back translations, back translation review, developer
review, harmonisation meeting, linguistic validation interviews
with 5 or 6 patients with type 2 diabetes and 2 proof readings.
A universal approach was used for French and Spanish with the
aim of developing a single Spanish and a single French version.
RESULTS: While the majority of wording was easily agreed
upon, certain words and phrases were more troublesome. Issues
and solutions included: The ﬁrst French suggestion, “medica-
ment,” did not take into account the possibility of more than
one medication. The ﬁnal agreement was on “medicament(s).”
“Extremely [satisﬁed]” cannot be translated literally in Mexico
as it is too formal. “Muy satisfecho” was selected as the best
alternative for Mexico and Spain. “How quickly” was misun-
derstood in pilot testing in Korea so this was changed to a more
idiomatic “the ‘fastness’.” “Tolerabilidad,” the original Spanish
translation, was found to be problematic during cognitive
debrieﬁng interviews and a simpler alternative was found. The
universal approach produced a single ﬁnal version for French
and Canadian French and very similar ﬁnal translations for
Spanish (for Spain) and Mexican Spanish. CONCLUSIONS: The
SOADA has been translated and linguistically validated and is
now available for use in 11 countries. The universal approach
used for Spanish and French was successful. A number of cul-
tural and linguistic issues became apparent and were resolved.
The measure is now appropriate for use in multinational trials.
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OBJECTIVES: Two patient self-report questionnaires were
developed for use by physicians. They were intended to assess
why diabetic patients were reluctant to switch their treatment
from oral hypoglycaemic agents to insulin or to step up their
insulin dosage when already treated with insulin. This study pre-
sents scores and psychometric validation for both questionnaires.
METHODS: Patients treated with oral hypoglycaemic agents (n
= 1582) and patients already treated with insulin (n = 1296) com-
pleted the questionnaire at baseline, Month 3 and Month 6. Psy-
chometric properties were assessed: 1) structural analysis by
Principal Component Analysis (PCA) with varimax rotation; 2)
internal consistency reliability determination (Cronbach’s alpha);
and 3) concurrent validation (Spearman correlation coefﬁcients
with the Fear of Self-Injecting (FSI) score of the Diabetes Fear of
Injecting and Self-testing Questionnaire (D-FISQ). The ability of
scores to predict the switch to an insulin treatment and increased
numbers of injections at the end of baseline visit was established
by calculating the Area Under the ROC Curve (AUC). RESULTS:
PCA analysis conﬁrmed the ﬁnal questionnaire structure of 14
items grouped into 3 dimensions (Acceptance/Motivation (AM),
Insulin treatment: fear and constraints (FC), and Reluctance to
be injected (RI)). Internal consistency reliability (Cronbach’s
alpha ranging from 0.74 to 0.82) and concurrent validity (FIS
